Related Experiment Videos
GM-CSF: a strong arteriogenic factor acting by amplification of monocyte function
I R Buschmann1, I E Hoefer, N van Royen
1Research Group for Experimental and Clinical Arteriogenesis at the Department of Cardiology and Angiology, Albert Ludwigs University of Freiburg, Hugstetter Strasse 55, 79106, Freiburg im Breisgau, Germany. buschmann@med1.ukl.uni-freiburg.de
Atherosclerosis
|December 4, 2001
Summary
Colony stimulating factor for monocytes (GM-CSF) prolongs monocyte lifespan, significantly enhancing arteriogenesis (collateral artery growth). This discovery offers a new therapeutic approach for improving blood flow after arterial occlusion.
Area of Science:
- Cardiovascular Biology
- Hematology
- Regenerative Medicine
Background:
- Circulating monocytes are crucial for arteriogenesis, the growth of collateral arteries to compensate for occlusions.
- Monocyte chemoattractant protein-1 (MCP-1) accelerates arteriogenesis, but its efficacy diminishes over time.
Purpose of the Study:
- To investigate if prolonging the monocyte life cycle with GM-CSF supports arteriogenesis.
- To explore the combined effects of GM-CSF and MCP-1 on arteriogenesis.
Main Methods:
- Continuous GM-CSF infusion in rabbits with femoral artery occlusion.
- Assessment of arteriogenesis via angiography and in vivo blood flow measurements.
- Analysis of monocyte apoptosis and cell behavior in vitro.
Main Results:
- GM-CSF significantly increased collateral artery number and size (2-fold) and maximal blood flow (5-fold).
- Combined GM-CSF and MCP-1 showed additive effects and extended MCP-1's therapeutic window.
- GM-CSF reduced monocyte apoptosis and potentially mobilized stem cells.
Conclusions:
- GM-CSF is a potent arteriogenic peptide that promotes collateral artery growth by extending monocyte lifespan.
- GM-CSF offers a novel therapeutic strategy for enhancing arteriogenesis and improving blood flow recovery.